News | Heart Failure | February 04, 2016

Failing Hearts Switch Fuels to Generate Energy

Findings suggest a new approach to treat early heart failure

February 4, 2016 — New research from scientists at Sanford Burnham Prebys Medical Discovery Institute (SBP) published in the journal Circulation, may lead to a new approach to help treat heart failure early in the disease.

Heart failure is the inability of the heart to pump sufficient blood to supply the body with oxygen. It can be caused by factors including high blood pressure, a previous heart attack, diabetes or family history. Most of the treatments currently available for heart failure are aimed at the later stages of disease.

More than 5 million people in the United States suffer from heart failure, according to the American Heart Association. Less than half of those with heart failure live five years after diagnosis.

The new study, led by Daniel Kelly, M.D., scientific director of SBP’s Lake Nona campus, provides fresh molecular insight into heart failure and may eventually lead to new therapeutic targets to prevent or slow progression of the disease.

“Our research shows that as the heart fails, it loses its ability to burn fatty acids—the building blocks of fat—and instead starts using ketone bodies as an alternative fuel. It’s almost like the heart is starving because it doesn’t have the enzymatic machinery to burn fat anymore,” said Kelly.

To better understand what metabolic changes occur in place of fatty acid-burning, Kelly’s team studied well-established mouse models of the early and late stages of heart failure.

The research team analyzed heart muscle cells to identify enzymes involved in metabolizing fuel that may ultimately become targets for therapies. They found that levels of an enzyme known as BDH1, involved in ketone metabolism, were twice as high in mice with both early stage and complete heart failure compared to normal animals.

“It was surprising that BDH1 was increased in the failing heart, because this is an enzyme that is involved in burning ketones,” Kelly said. “We find it more in brain and liver, but one wouldn’t expect it to be very active in the heart.”

The new results suggest that a heart in the midst of failure has the ability to reprogram itself to take in more ketones and use them as fuel. Future studies aimed at whether this is a productive versus a faulty adaptive fuel shift could lead to new therapeutic avenues for heart failure.

These findings offer good news for potential treatments, as the prevalence of heart failure in Americans is expected to increase 46 percent by the year 2030.

The study was performed in collaboration with researchers from Duke University and the Duke University School of Medicine, the University of Cologne and the University of Illinois at Chicago College of Medicine.

For more information: www.circ.ahajournals.org

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init